All Updates

All Updates

icon
Filter
Funding
Opna Bio raises USD 38 million in Series A funding; launches from stealth
Precision Medicine
Nov 21, 2022
This week:
M&A
N-able acquires Adlumin for USD 266 million to strengthen cybersecurity offerings
Next-gen Cybersecurity
Today
M&A
Bitsight acquires Cybersixgill for USD 115 million to enhance threat intelligence capabilities
Cyber Insurance
Today
M&A
Snowflake acquires Datavolo to enhance data integration capabilities for undisclosed sum
Generative AI Infrastructure
Today
M&A
Snowflake acquires Datavolo to enhance data integration capabilities for undisclosed sum
Data Infrastructure & Analytics
Today
M&A
Almanac acquires Gro Intelligence's IP assets for undisclosed sum
Smart Farming
Yesterday
Partnerships
Aduro Clean Technologies partners with Zeton to build hydrochemolytic pilot plant
Waste Recovery & Management Tech
Yesterday
Funding
Oishii raises USD 16 million in Series B funding from Resilience Reserve
Vertical Farming
Yesterday
Management news
GrowUp Farms appoints Mike Hedges as CEO
Vertical Farming
Yesterday
M&A
Rise Up acquires Yunoo and expands LMS monetization capabilities
EdTech: Corporate Learning
Yesterday
Product updates
Uber releases five new features for holiday travel season
Travel Tech
Yesterday
Precision Medicine

Precision Medicine

Nov 21, 2022

Opna Bio raises USD 38 million in Series A funding; launches from stealth

Funding

  • Clinical-stage drug developer Opna Bio has launched from stealth and raised USD 38 million in a Series A funding round led by Longitude Capital and Northpond Ventures with participation from Menlo Ventures. 

  • The funds will be used to develop its new fragile-X mental retardation protein (FMRP) inhibitor for treating patients with solid tumors. Cancer cells use FRMP to hide from the immune system. Moreover, it plans to advance its portfolio of five preclinical and clinical small molecule drug candidates acquired from Plexxikon Inc. OPN-2853, the company's lead research program, is currently in Phase 1/2 clinical trials in combination with ruxolitinib to treat myelofibrosis, a chronic bone marrow cancer. Additionally, a Phase 2 study of OPN-7486 for treating solid tumors is planned for 2023. 

  • Opna Bio discovers and develops cancer treatments using a precision medicine approach. Former Plexxikon CEO Gideon Bollag co-founded the company after Plexxikon was shut down by its parent company and Japanese pharmaceutical giant Daiichi Sankyo in March 2022 . Opna Bio is now led by Gideon Bollag. 

Contact us

Gain access to all industry hubs, market maps, research tools, and more
Get a demo
arrow
menuarrow

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.